Skip to main content

Table 4 Serious adverse events (SAEs)

From: Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

  Lapatinib + vinorelbine (N=44)
Subjects with any SAE, n (%) 22 (50)
With2 (5%) patients,n(%)  
 Neutropenia 15 (34)*
 Diarrhea 3 (7)
 Febrile neutropenia 3 (7)
 Abdominal pain 2 (5)
 Dehydration 2 (5)
Drug-related fatal SAEs, n (%) 0 (0)
  1. *Grade 4 laboratory abnormalities were protocol defined as SAEs.